Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $19.0152W HIGH $28.23
Volume
1.28 M
Value Traded
5.20 M
Short % Float
10.51%
-6.56%Week
-33.99%1 Month
-55.41%3 Month
-60.04%6 Month
-20.11%5 Year
-20.11%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.35 B
EPS (TTM)
-
P/E Ratio
-
Ent. Value
175.18 M
Total Shares
129.57 M
Float Shares
56.71 M
Insiders
56.26%
Institutions
44.00%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
KLRA Catalyst Timeline
Dated clinical, regulatory and corporate events for Kailera Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kailera Therapeutics, Inc.
23Total events
11Upcoming
8Tier-1 (high impact)
2026 to 2028Coverage
Upcoming catalysts 2
Event history 7
▲Oral PresentationRibupatide (KAI-9531)FiledPresentation
Phase 1 injection site data for ribupatide injection presented at EASD 2026
obesity or overweightsource ↗
▲Oral PresentationHRS-4729Presentation
Phase 1 data for HRS-4729 (KAI-4729) presented at EASD 2026
obesitysource ↗
▲Enrollment CompleteRibupatide (KAI-9531)FiledTrial
Completion of enrollment in KaiNETIC global Phase 3 program
obesity or overweightsource ↗
●IND SubmissionRibupatide (KAI-9531)FiledIND
IND for ribupatide oral active with U.S. FDA
obesitysource ↗
▲Enrollment CompleteRibupatide (KAI-9531)FiledTrial
Ribupatide injection Phase 2b high-dose trial fully enrolled
obesitysource ↗
▲Topline ReadoutHRS-7535Clinical Data
Positive topline data from OUTSTAND-2 trial in type 2 diabetes
type 2 diabetessource ↗
Past FDA Catalysts and PDUFA Decisions
How KLRA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-28 | KAI-4729 (HRS-4729) | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C51 / 100
Pipeline Score
$829M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.6x
rNPV / MCap
Top 16%
Micro Cap(rank 106 of 655)
Percentile Rank
Kailera Therapeutics, Inc. carries a moderate pipeline score (51/100), with $2.1B risk-adjusted pipeline value, led by Ribupatide (KAI-9531) in Obesity (Phase 3), across $188B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ribupatide (KAI-9531) Small moleculeNCT07458269 | Obesity | Phase 3 | RECRUITING | 3,790 | Jun 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every KLRA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ribupatide injection | obesity or overweight | Phase 1 | 2026-10-01 | 51 participants; 2 mg dose; mean weight loss of up to 16.0% from baseline; 67.3% mean reduction in liver fat content; mean reduction in body weight of 16.7%; 38.4% mean reduction in liver fat contentRead More | Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Tregoning KathleenOfficer (See Remarks) | Grant/Award | 175,000 175,000 held | $0.00 | 07/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KLRA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in KLRA for Q2 2026. | ||||
KLRA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KLRA ranks across every disease it competes in
Competitive Position is a premium feature
See how KLRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKLRA News
KLRA▼ -4%today
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
Kailera Therapeutics presented promising Phase 1 data for ribupatide injection at the EASD 2026 Annual Meeting, demonstrating the flexibility of injection sites without compromising safety. The data supports the use of alternative injection locations, and the company plans to advance its pipeline, including KAI-4729, into further clinical trials. Additional presentations from partner Hengrui Pharma highlighted significant findings in GLP-1 therapeutics.
Read more →KLRA▼ -4%today
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
Kailera Therapeutics has completed enrollment in its global Phase 3 KaiNETIC clinical program for ribupatide injection, a dual GLP-1/GIP receptor agonist aimed at treating obesity. The program includes three trials with topline data expected in mid-2028. This milestone is seen as a step closer to providing effective obesity treatment options.
Read more →KLRA▼ -5.6%on this news
Kailera Therapeutics to Participate in September Investor Conferences
Kailera Therapeutics announced its participation in two upcoming investor conferences in September 2026. The events include a fireside chat with key executives at the Bernstein Insights Healthcare Forum and the Stifel 2026 Virtual Cardiometabolic Forum. The company is focused on advancing its clinical-stage pipeline for obesity care, particularly its lead product candidate, ribupatide injection.
Read more →KLRAKailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
Kailera has reported its financial results for Q2 2026, highlighting significant advancements in its ribupatide program. The company has submitted an IND for an oral formulation of ribupatide to the U.S. FDA and plans to initiate global Phase 3 obesity trials in the first half of 2027. Additionally, the Phase 2b high-dose trial for ribupatide injection is fully enrolled, with data expected in mid-2027. The executive team has also been expanded to enhance technical operations.
Read more →KLRAKailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer
Kailera Therapeutics has appointed Nur Nicholson as Chief Technology Officer to lead its manufacturing and supply chain strategy. This move comes as the company aims to advance its late-stage obesity pipeline towards commercialization. Nicholson's extensive experience in technical operations is expected to bolster the company's efforts in this area.
Read more →KLRAKailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
Kailera Therapeutics announced positive topline results from two Phase 3 trials of HRS-7535, an oral GLP-1 receptor agonist. In the obesity trial, participants achieved up to 10.9% weight loss, while the diabetes trial showed significant reductions in HbA1c. Safety findings were consistent, with no liver safety signals reported. Kailera is also conducting a global Phase 2 trial to further optimize KAI-7535's profile.
Read more →KLRAKailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Kailera Therapeutics has appointed Kathleen Tregoning as Chief Corporate Affairs Officer. Tregoning, who has extensive experience in corporate affairs within the biopharmaceutical sector, will help navigate the complexities of the obesity treatment landscape. Her role will focus on stakeholder engagement and supporting innovation in obesity care as the company advances its clinical trials.
Read more →KLRAHengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Hengrui Pharma and Kailera Therapeutics presented clinical data on ribupatide, a dual agonist targeting GLP-1 and GIP receptors, at ADA 2026. The drug is being developed in both a once-weekly injection and a once-daily oral form for obesity treatment. Phase 2 trial results for the oral formulation were highlighted, showing positive outcomes.
Read more →KLRAKailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Kailera Therapeutics will present at the 2026 Jefferies Global Healthcare Conference on June 4. CEO Ron Renaud will discuss the company's innovative pipeline focused on obesity care, including their lead candidate, ribupatide injection, currently in Phase 3 trials. The presentation will be available via live webcast and archived for 90 days.
Read more →KLRAKailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates • Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline • Initiat
Kailera Therapeutics has reported its first quarter 2026 financial results, highlighting important advances in its clinical pipeline targeting obesity. The company initiated five late-stage global trials, including the KaiNETIC Phase 3 program for ribupatide injection. Additionally, positive clinical data was reported from trials in collaboration with their partner Hengrui in China, showcasing the potential of various compounds in development. With sufficient cash reserves to fund operations until mid-2028, Kailera aims to maintain momentum in advancing its diverse portfolio of therapies.
Read more →KLRA▼ -5.3%on this news
Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions
Hengrui Pharma and Kailera Therapeutics will present clinical results for ribupatide at the American Diabetes Association's 86th Scientific Sessions. The presentations will include data from a Phase 2 trial of oral ribupatide and a Phase 1 bridging study for the injectable form. These findings highlight the potential of ribupatide as a treatment option for obesity.
Read more →KLRAKailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Kailera Therapeutics has successfully closed its initial public offering, raising $718.8 million by offering 44,921,875 shares, including additional shares purchased by underwriters. The IPO was priced at $16.00 per share and is now listed on the Nasdaq under the ticker KLRA. The offering was managed by several prominent financial institutions.
Read more →KLRAKailera Therapeutics Announces Pricing of Initial Public Offering
Kailera Therapeutics has announced the pricing of its initial public offering, offering 39,062,500 shares at $16.00 each. The gross proceeds from this offering are projected to be $625 million, with trading set to begin on the Nasdaq under the ticker KLRA on April 17, 2026. The offering is expected to close on April 20, 2026, pending customary conditions.
Read more →About Kailera Therapeutics, Inc.
Headquarters180 THIRD AVENUE, WALTHAM, MA, 02451
Founded2024
BIOPHARMAWATCH ELITE PLUS
Trade the next KLRA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime